Harvard Bioscience (HBIO) EBIT (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of EBIT data on file, last reported at -$1.2 million in Q1 2026.

• EBIT for Q1 2026 came in at -$1.2 million, up 97.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.5 million (up 173.3% YoY), and the FY2025 annual result was -$12.0 million, down 388.29% from the prior year.
• EBIT eased to -$1.2 million in Q1 2026 per HBIO's latest filing, from $38.3 million in the prior quarter.
• Over five years, EBIT peaked at $38.3 million in Q4 2025 and troughed at -$49.7 million in Q1 2025.
• A 5-year average of -$1.1 million and a median of -$933000.0 in 2023 frame the typical range for EBIT.
• On a YoY basis, EBIT climbed as much as 6793.1% in 2022 and fell as far as 2708.37% in 2022.
• A 5-year view of EBIT shows it stood at $4.5 million in 2022, then slumped by 147.24% to -$2.1 million in 2023, then soared by 275.52% to $3.8 million in 2024, then surged by 916.09% to $38.3 million in 2025, then plunged by 103.06% to -$1.2 million in 2026.
• Business Quant data shows HBIO's EBIT at -$1.2 million in Q1 2026, $38.3 million in Q4 2025, and $197000.0 in Q3 2025.